Study guide
9.2 Coagulation Laboratory Testing: PT/INR, aPTT, Fibrinogen, Thrombin Time, and Mixing Studies
Philippine Medical Technologists Licensure Examination MTLE
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Clinical Chemistry: Laboratory Operations, Instrumentation, Reagents, Quality Assurance, and Safety
1.1 Specimen Collection, Preanalytical Variables, and Interferences 1.2 Clinical Chemistry Instrumentation, Photometry, and Automation 1.3 Quality Control, Westgard Rules, Calibration, and Laboratory Mathematics 1.4 Reagent Preparation, Laboratory Water, Glassware, Pipettes, and Centrifuges 1.5 Laboratory Safety: Chemical, Fire, Electrical, Biological, and Physical Hazards
2 Chapter 2: Clinical Chemistry: Carbohydrates, Lipids, Proteins, Non-Protein Nitrogen, and Liver Function
2.1 Glucose Homeostasis, Diagnostic Criteria for Diabetes Mellitus, and Glycemic Monitoring 2.2 Lipids, Lipoproteins, Apolipoproteins, and Coronary Heart Disease Risk Assessment 2.3 Serum Proteins, Albumin, Globulins, and Serum Protein Electrophoresis Patterns 2.4 Non-Protein Nitrogen Compounds: Urea, Creatinine, Uric Acid, and Renal Function 2.5 Liver Function Tests, Bilirubin Metabolism, and Jaundice
3 Chapter 3: Clinical Chemistry: Electrolytes, Blood Gases, Enzymology, Endocrinology, and Toxicology
3.1 Water Balance, Electrolytes, Osmolality, and Anion Gap Calculations 3.2 Blood Gas Analysis, Oxygenation, and Acid-Base Homeostasis 3.3 Clinical Enzymology: Enzyme Kinetics, Cardiac Biomarkers, and Hepatic and Pancreatic Enzymes 3.4 Endocrinology: Hormone Physiology and Endocrine Function Testing 3.5 Therapeutic Drug Monitoring and Clinical Toxicology
4 Chapter 4: Bacteriology: Specimen Management, Media, Staining, and Biosafety
4.1 Specimen Collection, Transport, Processing, and Microscopic Staining 4.2 Culture Media Classification, Quality Control, and Inoculation Techniques 4.3 Sterilization, Disinfection, Decontamination, and Biosafety Containment 4.4 Antimicrobial Susceptibility Testing Methods, Standardization, and Resistance Mechanisms
5 Chapter 5: Diagnostic Bacteriology: Major Pathogenic Bacteria
5.1 Medically Important Gram-Positive Cocci: Staphylococci, Streptococci, and Enterococci 5.2 Medically Important Gram-Negative Bacilli: Enterobacterales and Non-Fermenters 5.3 Fastidious, Microaerophilic, and Anaerobic Bacteria 5.4 Mycobacteria, Spirochetes, Atypical Bacteria, and Public Health Microbiology
6 Chapter 6: Medical Parasitology, Mycology, and Diagnostic Virology
6.1 Stool Examination Techniques and Intestinal Nematodes 6.2 Tissue Nematodes, Filarial Worms, Cestodes, and Trematodes 6.3 Medical Protozoology: Intestinal, Urogenital, and Blood/Tissue Protozoa 6.4 Medical Mycology: Yeasts, Dermatophytes, Dimorphic Fungi, and Opportunistic Molds 6.5 Clinical Virology: Viral Structure, Specimen Handling, and Diagnostic Methods
7 Chapter 7: Hematology: Specimen Collection, Routine Parameters, Instrumentation, and Manual Methods
7.1 Blood Specimen Collection, Anticoagulants, Preanalytical Variables, and Specimen Quality 7.2 Automated Cell Counting Principles, Complete Blood Count Parameters, and Erythrocyte Indices 7.3 Reticulocyte Evaluation, Supravital Staining, and Erythrocyte Sedimentation Rate 7.4 Manual Cell Counts, Manual Hemoglobin Methods, and Hematology Quality Control
8 Chapter 8: Hematology: Blood Cell Morphology, Bone Marrow, and Hematologic Disorders
8.1 Normal Erythropoiesis and Erythrocyte Morphologic Abnormalities 8.2 Anemias: Classification, Iron Deficiency, Megaloblastic, Hemolytic, and Hemoglobinopathies 8.3 Normal Leukopoiesis, Leukocyte Differential, and Non-Malignant White Cell Alterations 8.4 Hematologic Malignancies: Acute and Chronic Leukemias, Myeloproliferative and Lymphoproliferative Disorders 8.5 Peripheral Blood Smear Preparation and Staining, Bone Marrow Examination, and Cytochemistry
9 Chapter 9: Hemostasis: Coagulation and Platelet Function Testing and Hemostatic Disorders
9.1 Mechanisms of Primary and Secondary Hemostasis, Fibrinolysis, and Natural Inhibitors 9.2 Coagulation Laboratory Testing: PT/INR, aPTT, Fibrinogen, Thrombin Time, and Mixing Studies 9.3 Hemostatic and Thrombotic Disorders: Hemophilias, von Willebrand Disease, DIC, and Thrombophilias 9.4 Bleeding Time, Clotting Time, Platelet Function, and Special Hematology Tests
10 Chapter 10: Immunohematology: Blood Group Systems and Antiglobulin Testing
10.1 The ABO Blood Group System, Genetics, Subgroups, and Forward/Reverse Typing Discrepancies 10.2 The Rh Blood Group System, Weak D Testing, and Other Major Blood Group Systems 10.3 Antiglobulin Testing, Elution, Adsorption, and Special Antibody Procedures
11 Chapter 11: Blood Banking: Donor Operations, Component Therapy, and Adverse Reactions
11.1 Donor Selection, Physical Examination, Screening, and Mandatory Infectious Marker Testing 11.2 Blood Component Preparation, Storage, Expiration, and Indications for Transfusion 11.3 Pre-Transfusion Compatibility Testing and Transfusion Reactions 11.4 Hemolytic Disease of the Fetus and Newborn (HDFN) and Rh Immune Globulin
12 Chapter 12: Clinical Serology and Immunology
12.1 Principles of Immunology: Antigens, Antibodies, Complement, and Immune Responses 12.2 Serologic Testing Methodologies: Agglutination, Precipitation, Flocculation, and Labeled Immunoassays 12.3 Infectious Disease Serology: Syphilis, Viral Hepatitis Markers, HIV, Dengue, and Febrile Agglutinins 12.4 Autoimmune Serology, Hypersensitivity, Immunodeficiencies, and Histocompatibility (HLA)
13 Chapter 13: Clinical Microscopy: Urinalysis and Renal Pathology
13.1 Renal Physiology, Urine Formation, and Physical Examination of Urine 13.2 Chemical Examination of Urine: Reagent Strip Principles, Interferences, and Confirmatory Tests 13.3 Microscopic Examination of Urine Sediment: Cells, Casts, Crystals, and Contaminants 13.4 Renal Calculi, Glomerular/Tubular/Interstitial Renal Diseases, and Urinalysis Quality Control
14 Chapter 14: Clinical Microscopy: Body Fluids, Fecal Analysis, and Gastric, Duodenal, and Respiratory Specimens
14.1 Cerebrospinal Fluid Analysis: Collection, Cell Counts, Chemistry, and Microbiology 14.2 Serous Fluids (Pleural, Pericardial, Peritoneal: Transudates vs Exudates) and Synovial Fluid Analysis 14.3 Seminal Fluid and Amniotic Fluid Analysis 14.4 Fecal Analysis: Macroscopic, Microscopic, and Chemical Examination of Stool 14.5 Gastric Fluid, Duodenal Contents, Sputum, and Bronchoalveolar Specimens
15 Chapter 15: Histopathologic Techniques and Cytotechnology
15.1 Tissue Preservation, Fixation, Decalcification, and Processing Steps 15.2 Microtomy, Sectioning Artifacts, Hematoxylin and Eosin Staining, and Special Stains 15.3 Cytotechnology: Specimen Collection, Fixation, Papanicolaou Staining, and the Bethesda System 15.4 Special Procedures: Frozen Sections, Special Embedding, Immunohistochemistry, Electron Microscopy, Autopsy, Museum Techniques, and Laboratory Records
16 Chapter 16: Medical Technology Laws, Related Laws, and Ethics
16.1 Republic Act No. 5527 (The Philippine Medical Technology Act of 1969) and Key Amendments 16.2 Related Philippine Healthcare Laws, Code of Ethics, and Bioethics
9.2 Coagulation Laboratory Testing: PT/INR, aPTT, Fibrinogen, Thrombin Time, and Mixing Studies
Key Takeaways Explain This Topic AI
Preanalytical standardization for coagulation requires 3.2% (0.109 M) buffered sodium citrate with a 9:1 blood-to-anticoagulant ratio, hematocrit adjustment for values > 55 % >55\% > 55% , and preparation of platelet-poor plasma ( < 10 × 10 9 / L <10 \times 10^9/\text{L} < 10 × 1 0 9 / L ) to eliminate residual platelet phospholipids and platelet factor 4.
The Prothrombin Time (PT) assesses the extrinsic and common pathways and is reported as the International Normalized Ratio (INR) for Warfarin monitoring: INR = ( Patient PT / Mean Normal PT ) ISI \text{INR} = (\text{Patient PT} / \text{Mean Normal PT})^{\text{ISI}} INR = ( Patient PT / Mean Normal PT ) ISI , with therapeutic targets of 2.0–3.0 for venous thromboembolism and 2.5–3.5 for mechanical prosthetic valves.
The Activated Partial Thromboplastin Time (aPTT) monitors the intrinsic and common pathways and serves to titrate Unfractionated Heparin (target 1.5–2.5 times baseline or anti-Xa 0.3–0.7 IU/mL), whereas Low Molecular Weight Heparin (LMWH) requires chromogenic anti-Xa quantification.
The Thrombin Time (TT) evaluates conversion of fibrinogen to fibrin and is exceptionally sensitive to heparin; pairing with the heparin-insensitive snake venom Reptilase Time definitively differentiates heparin contamination from true hypofibrinogenemia or dysfibrinogenemia.
The 1:1 mixing study differentiates factor deficiencies from inhibitors: immediate correction indicates a factor deficiency; failure to correct immediately indicates an immediate inhibitor (such as Lupus Anticoagulant); and immediate correction followed by prolongation after 2-hour 37°C incubation is pathognomonic for an acquired Factor VIII inhibitor.
Last updated: October 2026
Coagulation Laboratory Testing: PT/INR, aPTT, Fibrinogen, Thrombin Time, and Mixing Studies
Diagnostic coagulation testing evaluates the functional integrity of secondary hemostasis, monitors parenteral and oral anticoagulant therapies, and localizes specific factor deficiencies and pathological circulating inhibitors. Because coagulation reactions are enzymatic processes occurring on phospholipid membranes in vitro, hemostasis assays are exceptionally sensitive to preanalytical variables, sample processing conditions, and reagent variations.
1. Preanalytical Standardization in Hemostasis Testing
According to Clinical and Laboratory Standards Institute (CLSI) H21-A5 guidelines, the preanalytical phase accounts for over 70% of analytical errors in the coagulation laboratory. Strict adherence to standardized protocols is essential for clinical validity:
Anticoagulant Formulation : The global standard anticoagulant is 3.2% (0.109 M) buffered sodium citrate in light-blue stoppered tubes. 3.8% (0.129 M) formulations are obsolete because their higher ionic concentration binds excess calcium, artifactually prolonging clotting times.
Blood-to-Anticoagulant Ratio : Evacuated collection systems are engineered to achieve an exact 9:1 volume ratio of whole blood to sodium citrate (9 parts blood to 1 part anticoagulant; citrate occupies 10% of total volume). Underfilled tubes (<90% of nominal fill volume) contain an excessive concentration of free, unchelated citrate relative to plasma. This excess citrate binds the calcium chloride ( C a C l 2 CaCl_2 C a C l 2 ) reagent added during testing, artifactually prolonging PT and aPTT.
Hematocrit Adjustment Formula : When a patient's hematocrit exceeds 55% ( > 0.55 >0.55 > 0.55 ) (e.g., in polycythemia vera, neonatal blood, or severe dehydration), the plasma volume fraction per unit volume of whole blood is significantly reduced. Consequently, the volume of standard citrate in the collection tube is excessive relative to the diminished plasma, causing artifactual prolongation of clotting times. The volume of citrate anticoagulant must be adjusted using the formula: C = ( 1.85 × 10 − 3 ) × ( 100 − Hct ) × V blood C = (1.85 \times 10^{-3}) \times (100 - \text{Hct}) \times V_{\text{blood}} C = ( 1.85 × 1 0 − 3 ) × ( 100 − Hct ) × V blood where C C C is the milliliters of 3.2% sodium citrate remaining in the tube, Hct \text{Hct} Hct is the patient's hematocrit in percent, and V blood V_{\text{blood}} V blood is the milliliters of whole blood to be added. Alternatively, the volume of citrate to remove or add can be determined by V citrate = 100 − Hct 595 − Hct × V total V_{\text{citrate}} = \frac{100 - \text{Hct}}{595 - \text{Hct}} \times V_{\text{total}} V citrate = 595 − Hct 100 − Hct × V total .
Preparation of Platelet-Poor Plasma (PPP) : Blood specimens must be centrifuged at 1 , 500 × g 1,500 \times g 1 , 500 × g for a minimum of 15 minutes (or equivalent validated g-force/time) to yield Platelet-Poor Plasma with a residual platelet count of < 10 × 10 9 / L <10 \times 10^9/\text{L} < 10 × 1 0 9 / L ( < 10 , 000 / μ L <10,000/\mu\text{L} < 10 , 000/ μ L ) . Residual platelets are problematic: freeze-thaw lysis releases intracellular Platelet Factor 4 (PF4) , which binds and neutralizes heparin in vitro, producing falsely shortened aPTT results in patients receiving unfractionated heparin. Furthermore, residual platelet membrane fragments provide exogenous phospholipids that neutralize antiphospholipid antibodies, producing false-negative lupus anticoagulant screens.
Specimen Storage and Stability Standards :
Prothrombin Time (PT) : Plasma or uncentrifuged specimens kept in sealed tubes are stable at room temperature ( 18 – 24 ∘ C 18\text{--}24^\circ\text{C} 18 – 2 4 ∘ C ) for up to 24 hours . Citrated blood for PT must NEVER be stored at refrigerated temperatures ( 2 – 8 ∘ C 2\text{--}8^\circ\text{C} 2 – 8 ∘ C ) because cold temperatures induce "cold activation" of Factor VII via plasma prekallikrein/FXIIa, spuriously shortening the PT, while also precipitating high-molecular-weight vWF multimers.
Activated Partial Thromboplastin Time (aPTT) : Stable for up to 4 hours at room temperature ( 18 – 24 ∘ C 18\text{--}24^\circ\text{C} 18 – 2 4 ∘ C ) if unheparinized. If the patient is receiving unfractionated heparin, plasma must be separated from cellular elements within 1 hour of venipuncture and tested within 4 hours to prevent in vitro neutralization by platelet-derived PF4.
Freezing Requirements : If testing cannot occur within stability windows, PPP must be aliquoted and frozen at − 20 ∘ C -20^\circ\text{C} − 2 0 ∘ C for up to 2 weeks, or − 70 ∘ C -70^\circ\text{C} − 7 0 ∘ C for up to 6 months to 1 year. Thawing must be performed rapidly in a 37 ∘ C 37^\circ\text{C} 3 7 ∘ C water bath for 3 to 5 minutes to prevent cryoprecipitation.
2. Clot Detection Instrumentation Principles
Automated coagulation analyzers employ three primary detection principles: ┌──────────────────────────────────────────────┐
- │ Clot Detection Methodologies │
- └──────────────────────┬───────────────────────┘
- │
- ┌───────────────────────────────────────┼──────────────────────────────────────┐
- ▼ ▼ ▼
- ┌──────────────┐ ┌──────────────┐ ┌──────────────┐
- │ Mechanical │ │Photo-Optical │ │ Chromogenic/ │
- │ Impedance │ │(Turbidimetric│ │ Immunologic │
- └──────┬───────┘ └──────┬───────┘ └──────┬───────┘
- │ │ │
- Wire loop or oscillating • Photometer monitors drop in • Synthetic peptide-pNA
- magnetic steel ball light transmittance / scatter cleavage at 405 nm
- Clot stops ball motion • Triggered by fibrin strands • Latex agglutination
- Immune to HIL interferences • Vulnerable to Lipemia, immunoassays for
- (Hemolysis, Icterus, Lipemia) Icterus, Hemolysis (HIL) D-dimer, vWF:Ag
Mechanical / Electromechanical Impedance :
Principle : Measures physical clot formation using an oscillating steel ball held in place by an electromagnetic field, or a moving wire probe. As fibrin polymers assemble, the increased mechanical viscosity displaces the ball from the electromagnetic sensor or breaks electrical contact.
Clinical Advantage : Mechanical systems are completely immune to optical interferences. They deliver accurate, reproducible clotting times in specimens with gross hemolysis, severe hyperbilirubinemia (icterus), or dense chylomicron lipemia.
Photo-Optical (Turbidimetric / Nephelometric) Detection :
Principle : An incandescent or LED light source passes monochromatic light (commonly 405 nm, 540 nm, or 660 nm) through the reaction cuvette. As thrombin cleaves fibrinogen and fibrin strands assemble into an opaque polymer lattice, light transmittance decreases (turbidimetry) or forward light scatter increases (nephelometry). The instrument records the clotting time when optical density exceeds a set threshold or reaches maximum velocity.
Limitation : High baseline optical absorbance from severe lipemia, hemolysis, or icterus can saturate optical sensors, causing "no-clot" optical errors or artifactually prolonged clotting times.
Chromogenic and Immunologic Methodologies :
Chromogenic Assays : Utilize synthetic oligopeptide substrates coupled to a chromophore, p p p -nitroaniline ( p NA p\text{NA} p NA ) . The targeted coagulation enzyme (e.g., Factor Xa, Thrombin, or Activated Protein C) cleaves the substrate, releasing free p NA p\text{NA} p NA , which absorbs strongly at 405 nm 405\text{ nm} 405 nm . The rate of absorbance increase is directly proportional to enzyme activity. Used for anti-Factor Xa heparin monitoring, antithrombin activity, and protein C activity.
Immunologic Turbidimetry : Employs latex microparticles coated with specific monoclonal antibodies directed against analyte epitopes (e.g., D-dimer, vWF antigen). Antigen-antibody cross-linking induces agglutination, increasing turbidity in proportion to analyte concentration.
- 3. Prothrombin Time (PT) and International Normalized Ratio (INR)
- Analytical Principle
The Prothrombin Time measures the functional integrity of the extrinsic pathway (Factor VII) and the common pathway (Factors X, V, II, and I) . Patient citrated PPP is pre-warmed to 37 ∘ C 37^\circ\text{C} 3 7 ∘ C . A combined reagent consisting of Tissue Thromboplastin (recombinant human or lipidated rabbit brain tissue factor + phospholipid extract) and 0.025 M Calcium Chloride ( C a C l 2 CaCl_2 C a C l 2 ) is added to initiate clotting. The elapsed time from reagent addition to clot formation is recorded in seconds.
Reference Interval : 11.0 to 13.5 seconds (varies by reagent lot and instrument).
Warfarin (Coumadin) Monitoring
Oral Vitamin K antagonists (Warfarin) inhibit the hepatic enzyme VKORC1 , blocking the cyclic regeneration of reduced Vitamin K hydroquinone. This impairs post-translational γ \gamma γ -carboxylation of Factors II, VII, IX, and X. Because Factor VII has the shortest biological half-life (4 to 6 hours) , its functional activity plummets within 24 hours of warfarin initiation, making the PT the primary assay for oral anticoagulant monitoring.
The International Normalized Ratio (INR)
Because different commercial thromboplastin reagents vary in their sensitivity to factor deficiencies, raw PT seconds cannot be compared between laboratories. In 1983, the World Health Organization (WHO) introduced the International Normalized Ratio (INR) to standardize PT reporting:
INR = ( Patient PT (seconds) Mean Normal PT (MNPT, seconds) ) ISI \text{INR} = \left( \frac{\text{Patient PT (seconds)}}{\text{Mean Normal PT (MNPT, seconds)}} \right)^{\text{ISI}} INR = ( Mean Normal PT (MNPT, seconds) Patient PT (seconds) ) ISI
Mean Normal Prothrombin Time (MNPT) : The geometric mean PT calculated from at least 20 to 30 freshly collected healthy adult donor plasmas, verified with each new lot of thromboplastin reagent and instrument combination.
International Sensitivity Index (ISI) : A calibration exponent assigned to each commercial lot of thromboplastin by calibration against the WHO primary international reference preparation (human recombinant thromboplastin, assigned ISI = 1.0 \text{ISI} = 1.0 ISI = 1.0 ). High-sensitivity reagents have an ISI near 1.0 (e.g., 0.90 to 1.10). Reagents with higher ISI values (e.g., 1.8 to 2.2) are less responsive to factor reductions.
- Clinical INR Targets
- Healthy / Non-anticoagulated : 0.8 to 1.2
- Standard Therapeutic Range (VTE, DVT, PE, Atrial Fibrillation, Bioprosthetic Valves) : 2.0 to 3.0
- High-Intensity Range (Mechanical mitral or higher-risk mechanical heart valves) : 2.5 to 3.5
Critical Panic Alert : INR ≥ 4.5 – 5.0 \text{INR} \ge 4.5\text{--}5.0 INR ≥ 4.5 – 5.0 (indicates severe hemorrhage risk; requires urgent clinical notification and possible reversal with Vitamin K, Four-Factor Prothrombin Complex Concentrate [4F-PCC], or FFP).
- 4. Activated Partial Thromboplastin Time (aPTT) and Heparin Monitoring
- Analytical Principle
The aPTT measures the functional activity of the intrinsic pathway (Factors XII, XI, IX, VIII, Prekallikrein, HMWK) and the common pathway (Factors X, V, II, and I) .
Procedure : Citrated PPP is mixed with Partial Thromboplastin (phospholipid extract lacking tissue factor, substituting for platelet membranes) and a negatively charged particulate surface activator ( micronized silica, celite, kaolin, or ellagic acid ). The mixture is incubated at 37 ∘ C 37^\circ\text{C} 3 7 ∘ C for 3 to 5 minutes to permit complete contact activation of Factor XII and Prekallikrein. Clotting is initiated by adding pre-warmed 0.025 M C a C l 2 CaCl_2 C a C l 2 .
Reference Interval : 25.0 to 35.0 seconds (prolongation typically occurs when any intrinsic factor drops below 30% to 40% of normal activity).
Unfractionated Heparin (UFH) Monitoring
Unfractionated heparin acts by binding Antithrombin via a high-affinity pentasaccharide sequence, accelerating AT-mediated neutralization of Factor IIa (thrombin) and Factor Xa. The therapeutic window for UFH was historically defined as 1.5 to 2.5 times the patient's baseline aPTT (corresponding to approx. 60 to 85 seconds ). However, CLSI guidelines mandate that every laboratory establish an institution-specific aPTT therapeutic range calibrated against a chromogenic anti-Factor Xa activity range of 0.3 to 0.7 IU/mL .
Low Molecular Weight Heparin (LMWH)
Low Molecular Weight Heparins (enoxaparin, dalteparin) have shorter polysaccharide chains ( < 18 <18 < 18 saccharide units) that can bind antithrombin to neutralize Factor Xa, but lack the chain length required to bridge antithrombin to thrombin. Consequently, LMWH exhibits an anti-Xa to anti-IIa activity ratio of 3:1 to 4:1 and does NOT significantly prolong the aPTT . Routine monitoring is unnecessary, but when clinically indicated (pregnancy, renal insufficiency with GFR < 30 mL/min <30\text{ mL/min} < 30 mL/min , extreme obesity), LMWH is monitored strictly using a chromogenic anti-Factor Xa assay (therapeutic peak target: 0.6 to 1.0 IU/mL for twice-daily dosing, sampled 4 hours post-subcutaneous injection).
- 5. Thrombin Time (TT), Reptilase Time, and Quantitative Fibrinogen (Clauss Method)
- Thrombin Time (TT / Thrombin Clotting Time)
Principle : A low, standardized concentration of exogenous bovine or human thrombin (~1.5 to 3.0 NIH units/mL) is added to neat patient PPP. Bypasses all upstream cascade factors, measuring exclusively the conversion of fibrinogen to fibrin.
Reference Interval : 15.0 to 20.0 seconds .
Causes of Prolongation : Hypofibrinogenemia ( < 100 mg/dL <100\text{ mg/dL} < 100 mg/dL ), dysfibrinogenemia, elevated fibrin degradation products (FDPs), and the presence of heparin or direct thrombin inhibitors (dabigatran, argatroban, bivalirudin).
Reptilase Time
Principle : Clotting is triggered using Reptilase , an enzyme isolated from the venom of the South American pit viper Bothrops atrox . Reptilase cleaves only fibrinopeptide A from fibrinogen to form fibrin polymers. Crucially, Reptilase is completely insensitive to heparin and antithrombin .
Diagnostic Differentiation Table :
- Condition Thrombin Time (TT) Reptilase Time
- Heparin Contamination / UFH Therapy Markedly Prolonged NORMAL
- Direct Thrombin Inhibitors (Dabigatran) Markedly Prolonged NORMAL
- Hypofibrinogenemia ( < 100 mg/dL <100\text{ mg/dL} < 100 mg/dL ) Prolonged Prolonged
- Dysfibrinogenemia Prolonged Prolonged
- Severe FDP Elevation (DIC) Prolonged Prolonged
- Quantitative Fibrinogen: The Clauss Method
Principle : A modified, high-concentration thrombin clotting assay. Patient PPP is diluted 1:10 with imidazole buffer. A high concentration of bovine thrombin (approx. 100 NIH units/mL ) is added. Under these conditions, the clotting time is strictly inversely proportional to the logarithm of functional fibrinogen concentration in the plasma. The high excess of thrombin renders the assay insensitive to therapeutic heparin concentrations (up to ~1–2 IU/mL).
Reference Interval : 200 to 400 mg/dL ( 2.0 – 4.0 g/L 2.0\text{--}4.0\text{ g/L} 2.0 – 4.0 g/L ).
Critical Low Value : < 100 mg/dL <100\text{ mg/dL} < 100 mg/dL (indicates severe risk of microvascular hemorrhage in DIC, trauma coagulopathy, or postpartum hemorrhage).
6. Mixing Studies (1:1 Mixing Test Algorithm)
When a patient presents with an unexplained prolonged PT or aPTT, a 1:1 Mixing Study is the diagnostic procedure of choice to differentiate a coagulation factor deficiency from a circulating inhibitor (such as a Lupus Anticoagulant or specific factor antibody): Unexplained Prolonged PT or aPTT
- │
- 1:1 Mix: Patient Plasma + PNP
- │
- ┌────────────────────────┴────────────────────────┐
- ▼ ▼
Immediate Clotting Time: Immediate Clotting Time:
- CORRECTS to Normal FAILS TO CORRECT
- │ │
- Hold 1:1 Mix & PNP at ▼
- 37°C for 2 Hours **Immediate Inhibitor**
- │ • Lupus Anticoagulant
- ┌─────────────┴─────────────┐ • Direct Oral Anticoagulant
- ▼ ▼
- Clotting Time REMAINS Clotting Time BECOMES
- CORRECTED PROLONGED
- │ │
- ▼ ▼
- **Factor Deficiency** **Time- & Temp-Dependent**
- Hemophilia A (VIII) **Specific Inhibitor**
- Hemophilia B (IX) • Factor VIII Inhibitor
- Factor XI Deficiency (Acquired Hemophilia A)
Preparation : Equal parts ( 1:1 ratio ) of patient citrated PPP and Pooled Normal Plasma (PNP) are mixed. PNP is prepared from a pool of ≥ 20 \ge 20 ≥ 20 healthy donors and contains approximately 100% (1.0 U/mL) of all clotting factors.
Immediate Test : The clotting assay (PT or aPTT) is performed immediately on the mixture:
Immediate Correction : If the clotting time normalizes (bringing the time into the laboratory's reference range, or producing a Rosner Index / Index of Circulating Anticoagulant < 11 % <11\% < 11% ), it indicates that the 50% factor concentration provided by the PNP restored hemostatic function. This points toward a Factor Deficiency .
Failure to Correct : If the clotting time remains prolonged, an immediate-acting circulating inhibitor is present that neutralizes the factors or phospholipids supplied by the PNP. The most frequent etiology is a Lupus Anticoagulant (antiphospholipid antibody), or high-concentration heparin / direct oral anticoagulants.
Incubated Test (37°C for 1 to 2 Hours) :
If immediate correction occurs, the 1:1 mix, an aliquot of patient plasma, and an aliquot of PNP are incubated side-by-side at 37 ∘ C 37^\circ\text{C} 3 7 ∘ C for 120 minutes :
Prolonged After Incubation : If the mixture was normal immediately but becomes significantly prolonged after incubation, it proves the presence of a time- and temperature-dependent specific inhibitor , which is pathognomonic for an acquired autoantibody against Factor VIII (Factor VIII inhibitor) . Antibodies to Factor VIII have slow binding kinetics that require prolonged warm incubation to bind and neutralize Factor VIII supplied by the PNP.
Persistent Correction : If the mix remains within normal limits after incubation, an uncomplicated congenital or acquired Factor Deficiency is confirmed.
7. Quantitative D-dimer Immunoassay
Principle : Automated immunoturbidimetric assay employing polystyrene latex particles coated with mouse monoclonal antibodies directed specifically against the cross-linked neoepitope of the D-dimer fragment . Because this epitope is created exclusively when Factor XIIIa forms covalent isopeptide cross-links between adjacent D domains of fibrin polymers and is subsequently exposed by plasmin degradation, the antibody exhibits zero cross-reactivity with native fibrinogen or non-cross-linked fibrinogen degradation products (fragments X, Y, D, E).
Units of Reporting : Reported as either Fibrinogen Equivalent Units (FEU) (based on molecular weight of fibrinogen, ~340 kDa) or D-Dimer Units (DDU) (based on molecular weight of the D-dimer fragment, ~180 kDa). 1.0 μ g/mL FEU ≈ 0.5 μ g/mL DDU 1.0\text{ }\mu\text{g/mL FEU} \approx 0.5\text{ }\mu\text{g/mL DDU} 1.0 μ g/mL FEU ≈ 0.5 μ g/mL DDU .
Clinical Utility : Features an exceptional Negative Predictive Value ( > 98 % >98\% > 98% ) when values are below the clinical cutoff ( < 500 μ g/L FEU <500\ \mu\text{g/L FEU} < 500 μ g/L FEU or < 0.50 μ g/mL FEU <0.50\ \mu\text{g/mL FEU} < 0.50 μ g/mL FEU ). A normal D-dimer safely rules out Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in outpatients categorized with low or moderate pre-test clinical probability (via Wells score), eliminating the need for venous duplex ultrasonography or CT pulmonary angiography. Markedly elevated in Disseminated Intravascular Coagulation (DIC), sepsis, surgery, trauma, and extensive thrombosis.
8. Summary Decision Table: Coagulation Profiles & Mixing Study Interpretation
Clinical / Laboratory Pattern PT aPTT TT Reptilase 1:1 Mix (Immediate) 1:1 Mix (2 hr Incubated) Primary Etiology
Isolated Extrinsic Defect Prolonged Normal Normal Normal Corrects Corrects Factor VII deficiency, early Warfarin, mild liver disease
Isolated Intrinsic Defect Normal Prolonged Normal Normal Corrects Corrects Factor VIII (Hem A), IX (Hem B), XI, or XII deficiency
Common Pathway Defect Prolonged Prolonged Normal Normal Corrects Corrects Factor X, V, or II deficiency; combined vit K deficiency
Lupus Anticoagulant Normal/Prol Prolonged Normal Normal No Correction No Correction Antiphospholipid syndrome (antiphospholipid autoantibody)
Acquired Factor VIII Inhibitor Normal Prolonged Normal Normal Corrects Prolongs Time-dependent autoantibody (acquired hemophilia A)
Heparin Contamination Normal/Prol Prolonged Prolonged NORMAL Variable Variable Unfractionated heparin flush or line draw artifact
Severe DIC / Afibrinogenemia Prolonged Prolonged Prolonged Prolonged Variable Variable Consumption coagulopathy, severe hypofibrinogenemia